- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Mallinckrodt plc
Headquarters: Staines-upon-Thames, United Kingdom
Website: http://www.mallinckrodt.com
Year Founded: 1867
Status: Private
BioCentury | Aug 3, 2024
Management Tracks
Dannielle Appelhans to lead Cour
Plus: Context hires Ullmann, Andreas, and updates from Galectin, Exagen, Candid, Amgen and Hummingbird
BioCentury | Aug 18, 2023
Management Tracks
CSL names first chief sustainability officer
Plus: Jones hired as CCO at NewAmsterdam, and updates from Foresight, Kronos, Antheia and more
BioCentury | Mar 28, 2023
Management Tracks
New strategy heads at Genmab and Codagenix
Plus: OncoVerity names Colao CEO and Smith CMO, and updates from Silence, Mannkind, Immuneering and more
BioCentury | Jan 13, 2023
Management Tracks
Richardson becomes CSO at Mallinckrodt
Plus: XtalPi hires new COO for U.S. operations, and updates from Jupiter, Big Health and Edelman Global
BioCentury | Jan 9, 2023
Management Tracks
Sanofi’s Zehnder to lead CureVac
Plus: new CEOs at Novavax, Intergalactic, Evoq and Helsinn, and updates from ADARx, Acadia and more
BioCentury | Sep 20, 2022
Management Tracks
Luo joins Everest as CEO
Plus Hitchcock named CSO at Takeda, and updates from Viracta, Agios, Aktis and more
BioCentury | Sep 17, 2022
Product Development
Sept. 16 Quick Takes: AZ’s danicopan meets in Phase III
Plus updates from Alnylam, Mallinckrodt, Neuron23-Qiagen and more
BioCentury | Jul 14, 2022
Management Tracks
Cantrell joins Brii as CBO
Plus Chan Lee to be general counsel at BeiGene and updates from CytoDyn, Kezar, Anaveon, Fulcrum and more
BioCentury | Jul 1, 2022
Finance
June 30 Quick Takes: Flagship re-ups in Seres as biotech nears market; new PDUFA for Provention
Novartis pays $100M for a priority review voucher; plus updates from AstraZeneca, Pfizer, Peter Marks and more
BioCentury | Mar 23, 2022
Emerging Company Profile
Ocelot chasing hepatorenal disease with $36M round, candidate from Ferring
Three VCs have backed single-asset Ocelot Bio to advance a peptide therapeutic for a recently redefined disorder with new treatment guidelines
Items per page:
1 - 10 of 133